Key result
RBC-coated paclitaxel nanosuspension yields ~79% rapid cumulative release, outperforming uncoated controls.
Why the study?
In view of the longevity and innate immune escape of red blood cells, this study designed a red blood cell membrane-coated paclitaxel nanosuspension and investigated its physicochemical properties and antitumor effect in vitro.
Absolute Event Rate: 79% vs 25%
p-value: p=<0.05
Red blood cell membrane coating of paclitaxel nanosuspension improves its solubility, stability, and in vitro cytotoxicity against HepG2 cells.
RBC-coated paclitaxel nanosuspension may enhance delivery; hypothesis-generating for nanosuspensions, requiring in vivo validation before any clinical consideration.
In view of the longevity and innate immune escape of red blood cells, this study designed the red blood cell membrane-coated paclitaxel nanosuspension [RBC-(PTX)NS] and investigated its physicochemical properties and antitumor effect in vitro. Paclitaxel nanosuspension [(PTX)NS] was prepared by ultrasonic precipitation and then RBC-(PTX)NS by ultrasonic coating. The formulation of(PTX)NS was optimized with Box-Behnken method and indexes of particle diameter, zeta potential, and stability. The morphology, particle diameter, stability, in vitro dissolution, and antitumor effect of(PTX)NS and RBC-(PTX)NS were characterized. The results showed that the particle diameter and zeta potential were(129.38±0.92) nm and(-22.41±0.48) mV, respectively, for the optimized(PTX)NS, while(142.5±0.68) nm and(-29.85±0.53) mV, respectively, for RBC-(PTX)NS. Under the transmission electron microscope,(PTX)NS was spherical and RBC-(PTX)NS had obvious core-shell structure. RBC-(PTX)NS remained stable for 5 days at 4 ℃. The in vitro dissolution test demonstrated that the cumulative release rate of RBC-(PTX)NS reached 79% within 20 min, which was significantly higher than that(25%) of(PTX)NS(P<0.05). As evidenced by MTT assay, RBC-(PTX)NS highly inhibited the proliferation of HepG2 cells in a dose-dependent manner. The cell membrane-coated nano-preparation preparation method is simple and reproducible. It improves the solubility of PTX and endows RBC-(PTX)NS with higher stability and stronger cytotoxicity. Thus, it is a new method for the delivery of PTX via nanocrystallization.
No takes yet. Share an insight, caveat, or question.
Fan et al. (2022) studied Cancer (in vitro HepG2 cells). RBC-(PTX)NS vs. (PTX)NS was evaluated on Cumulative release rate within 20 min (p=<0.05). Red blood cell membrane-coated paclitaxel nanosuspension achieved a cumulative release rate of 79% within 20 minutes, significantly higher than the 25% of uncoated nanosuspension (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: